CCL18 and inflammatory bowel disease: Further studies are therefore necessary to ascertain whether the increased expression of the Ccr8 receptor and its ligands CCL1 and CCL18 in human IBD is contributing to type 2 immunity mediated tissue repair or supports innate type 1 immunity, which has been implicated in CD pathophysiology (44).